Abstract Details

Title Aerobic Training and Potential Neurogenesis in Progressive Multiple Sclerosis: Focus on the Hippocampus and the Subventricular Zone

Topic Multiple Sclerosis

Presentation(s) S8 - Multiple Sclerosis: Imaging, Biomarkers, and Environmental Exposures (4:30 PM-4:42 PM)

Poster/Presentation
Number 006

Objective To assess the effects of aerobic exercise on the volume of the hippocampus and its subfields and on diffusivity measures of the subventricular zone (SVZ) in patients with progressive multiple sclerosis (MS).

Background Neurogenesis may occur in the dentate gyrus (DG) of the hippocampus and the SVZ in the adult mammalian brain. In MS patients, aerobic training may exert a neuroprotective role on the brain by stimulating neurogenesis in DG and SVZ, which could translate into measurable volumetric or microstructural alterations within these two regions, but further evidence is needed to confirm this hypothesis.

Design/Methods We retrospectively analyzed data from 84 patients with progressive MS enrolled at four sites participating in the CogEx MRI substudy. Thirty-nine patients performed aerobic training, while 45 patients undertook a balance- and stretching-based sham exercise intervention. Both groups trained twice weekly for twelve weeks. At baseline, post-intervention and six-month follow-up, patients underwent MRI assessment on a 3.0 T scanner. FreeSurfer’s longitudinal processing stream was used to analyze hippocampal subfields’ volumes. Fractional anisotropy and mean diffusivity were extracted from the SVZ and the thalamus (as control region).

Results There were no differences between the two groups in the assessed variables at baseline (p≥0.070). The DG showed a significant volume increase post-intervention in the aerobic exercise group (mean change=0.63%, 95% confidence interval [95%CI]=0.04%;1.22%, p=0.035), but not in the sham group (mean change=-0.26%, 95%CI=-0.81%;0.28%, p=0.337). DG volume increase was significantly greater in the aerobic group compared to the sham group (p=0.029). No significant volumetric changes were found in the other hippocampal subfields nor in the diffusivity metrics of the SVZ (p≥0.057). No significant changes in either group were found between end of training and the six-month follow-up (p≥0.061)

Conclusions Aerobic exercise increases DG volume in progressive MS patients but does not modify microstructural integrity of the SVZ.

Authors/Disclosures
Tetsu Morozumi, PT (Ospedale San Raffaele S.r.l.) PRESENTER	Mr. Morozumi has nothing to disclose.
Paola Valsasina	Paola Valsasina has nothing to disclose.
Paolo Preziosa (Ospedale San Raffaele)	Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
Alessandro Meani	Alessandro Meani has nothing to disclose.
Rob Motl (UIC)	No disclosure on file
Maria P. Amato, PhD (Ospedale Di Careggi)	Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOU Careggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi genzyme. The institution of Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene BMS. The institution of Dr. Amato has received research support from Merck. The institution of Dr. Amato has received research support from Biogen. The institution of Dr. Amato has received research support from Roche.
Giampaolo Brichetto, MD, PhD (Italian MS Society)	Giampaolo Brichetto, MD, PhD has received personal compensation for serving as an employee of Italian MS Society.
Vincenzo Daniele Boccia	Vincenzo Daniele Boccia has nothing to disclose.
Jeremy S. Chataway, MD	Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janseen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NerveGen. Dr. Chataway has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis.
Nancy Chiaravalloti	The institution of Nancy Chiaravalloti has received research support from NIH. The institution of Nancy Chiaravalloti has received research support from NIDILRR.
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.
Ulrik Dalgas	Ulrik Dalgas has received personal compensation for serving as an employee of Roche. Ulrik Dalgas has received personal compensation for serving as an employee of Bristol Meyers Squibb.
John DeLuca, PhD, ABPP (Kessler Foundation)	Dr. DeLuca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. DeLuca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. DeLuca has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Celgene. Dr. DeLuca has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. DeLuca has received research support from Biogen.
Rachel A. Farrell, MD (National Hospital for Neurology and Neurosurgery)	The institution of Dr. Farrell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharma / Jazz. The institution of Dr. Farrell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merz.
Peter Feys	Peter Feys has nothing to disclose.
Jennifer Freeman	Jennifer Freeman has nothing to disclose.
Matilde Inglese, MD, PhD (University of Genoa)	Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal.
Cecilia Meza (Sunnybrook Research Institute)	Cecilia Meza has nothing to disclose.
Amber Salter, PhD (UT Southwestern Medical Center)	Dr. Salter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gryphon Bio. Dr. Salter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abata Therapeutics. Dr. Salter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sora Neuroscience. Dr. Salter has stock in Owl Therapeutics. The institution of Dr. Salter has received research support from National Multiple Sclerosis Society. The institution of Dr. Salter has received research support from Department of Defense Congressionally Directed Medical Research Program. The institution of Dr. Salter has received research support from Consortium of Multiple Sclerosis Centers.
Brian Sandroff	The institution of Brian Sandroff has received research support from NIH, NIDILRR, National MS Society.
Anthony Feinstein, MD (Sunnybrook Health Sciences Centre)	Anthony Feinstein, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis, Biogen, Roche and Sanofi-Genzyme. The institution of Anthony Feinstein, MD has received research support from Multiple Sclerosis Society of Canada. Anthony Feinstein, MD has received publishing royalties from a publication relating to health care.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)	Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Maria A. Rocca (Neuroimaging Research Unit)	Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.

��ɫ��

��ɫ��